Meg Spriggs
Senior Research Associate in Psychedelic Research
Papers
Trials
Key Impact
Notable for her multidisciplinary contributions to clinical and qualitative research on psychedelic-assisted therapies, particularly work on psilocybin for eating disorders and methodological guidance on patient/public involvement and safety.
Background & Research
Meg Spriggs is a senior research associate affiliated with the Psychedelic Research Group at Imperial College London and a frequent collaborator with leading investigators in contemporary psychedelic science. Her work spans clinical trial protocols, neuroimaging and electrophysiology studies, and mixed-methods qualitative research; she has acted as a lead research associate on protocol development for psilocybin-assisted therapy studies in anorexia nervosa and has co-authored empirical and methodological papers on early psilocybin exposure, LSD-induced connectivity changes, and DMT phenomenology.
Spriggs has published and contributed to research on moderators of psychedelic-induced personality change, the effects of antidepressant discontinuation prior to psilocybin therapy, and the mental‑health effects of psychedelics in people reporting eating disorders. She has also been active in work on patient and public involvement, ethics and safety frameworks for psychedelic research, and scoping reviews of clinical research in younger populations—bringing clinical trial experience together with qualitative and participatory methods to inform safer, more patient-centred psychedelic research.